Restenosis News and Research

RSS

Restenosis means the reoccurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed. This is usually restenosis of an artery, or other blood vessel, or possibly a vessel within an organ.

Novel drug-coated balloon technology adopted in niche applications across Europe: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, novel drug-coated balloon technology is being adopted in niche applications throughout Europe. This market will continue to grow as physicians increasingly use the technology in cases where other devices may not be suitable.

4 Nov 2010

Atrium completes enrollment in iCAST Atrium Registry Ultrasound Study

Atrium Medical Corporation is pleased to announce that the final patient was recently enrolled in the iCAST™ Atrium Registry Ultrasound Study (iCARUS). This study is a prospective, multi-center clinical trial studying the safety and efficacy of the Atrium iCAST™ Balloon Expandable Covered Stent in patients with occlusive disease of the iliac artery.

2 Nov 2010

Spectranetics 2010 third quarter revenue increases 3% to $29.6 million

Spectranetics Corporation today reported financial results for the three and nine months ended September 30, 2010.

27 Oct 2010

EES implantation reduces restenosis, repeat revascularization in patients with calcified culprit lesions

Two new studies have determined that everolimus-eluting stent (EES) implantation reduced the incidence of restenosis and repeat revascularization in patients with calcified culprit lesions, and had fewer clinical events. Results show the rate of major cardiac adverse events in EES-treated patients with calcified lesions were higher than in those for noncalcified lesions, but remained lower than the results of previously reported stent studies.

22 Oct 2010

Carotid artery stenting increases risk of death, stroke

For patients with blockages in the carotid artery that supplies blood to the brain, carotid artery stenting (a non-surgical treatment) appears to be associated with an increased risk of both short- and long-term adverse outcomes when compared with surgical treatment (carotid endarterectomy), according to a meta-analysis of previously published studies that was posted online today and will appear in the February 2011 print issue of Archives of Neurology, one of the JAMA/Archives journals.

12 Oct 2010

OrbusNeich completes enrollment in randomized clinical study of Genous Bio-engineered R stent in China

OrbusNeich today reported the completion of patient enrollment in a randomized clinical study of its Genous Bio-engineered R stent at 11 sites in China.

12 Oct 2010

IN.PACT drug-eluting balloons show promising results for superficial femoral artery disease treatment

Advancing research on drug-eluting balloons for the treatment of coronary and peripheral artery disease, Medtronic, Inc., today announced the latest results from the IN.PACT drug-eluting balloon (DEB) clinical program presented last week at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference.

29 Sep 2010

Clinical trial results of Genous Bio-engineered R stent, EPC capture technology presented at TCT 2010

OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture Technology: from Genous to Combo" at Transcatheter Cardiovascular Therapeutics 2010 in Washington.

27 Sep 2010

Boston releases HORIZONS-AMI trial data

Angiotech Pharmaceuticals, Inc. announced that its corporate partner, Boston Scientific Corporation, has released three-year follow-up data from the HORIZONS-AMI trial.

27 Sep 2010

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America.

24 Sep 2010

Lutonix presents data on Moxy Drug Coated Balloon Catheter at TCT meeting

Lutonix, Inc., headquartered in Minneapolis, MN, today announced six-month data from three separate drug coated balloon studies presented at the TransCatheter Therapeutics (TCT) meeting this week demonstrated the ability of the Moxy Drug Coated Balloon Catheter to inhibit restenosis in both peripheral and coronary arteries.

24 Sep 2010

InspireMD to launch MGuard Prime MicroNet stent system at TCT Conference

InspireMD, developers of the novel MGuard(TM) coronary MicroNet stent system, will introduce MGuard Prime at its booth #2052 at the TCT Conference in Washington DC, September 23-25, 2010. MGuard Prime presents an advanced Co-Cr Design of 80 micron struts along with InspireMD's unique MicroNet(R) Mesh Technology.

23 Sep 2010

TAXUS Element Stent has comparable levels of TLR and late loss in diabetic and non-diabetic patients

Boston Scientific Corporation today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the performance of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients. Results demonstrated that despite the known increased risk of restenosis for diabetics versus non-diabetics in patients undergoing coronary revascularization, the TAXUS Element Stent had comparable levels of target lesion revascularization (TLR) and late loss in both diabetic and non-diabetic patients.

23 Sep 2010

Boston announces TAXUS ATLAS clinical trial data for complex lesions

Boston Scientific Corporation today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS Liberte Paclitaxel-Eluting Stent System in a variety of lesions and patient groups.

23 Sep 2010

ESC recommends InspireMD MGuard mesh technology for thrombotic lesions

InspireMD Ltd., a medical device company engaged in the development and commercialization of the mesh based MGuard(TM) stent systems, is proud to report that mesh-based protection, is now recommended for use in the new Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC). According to the latest European Society of Cardiology Guidelines, published at the ESC Congress last week, "Mesh-based protection may be considered for PCI of highly thrombotic or SVG lesions" - it has received a class IIb recommendation.

9 Sep 2010

Late breaking clinical trials in interventional cardiovascular medicine to be presented at TCT 2010

Clinical trials in a variety of areas within interventional cardiovascular medicine that will be presented at TCT 2010 will directly affect the way that people with cardiovascular disease are treated. Breakthroughs in science and medical research, presented exclusively at TCT, will lead to new treatments that are minimally invasive and involve shorter recovery times. Among the topics being covered are stenting in the femoral artery, polymer-free drug-eluting stents, valves and drug-eluting balloons used in angioplasty.

8 Sep 2010

InfraReDx receives 510(k) clearance to market LipiScan IVUS Coronary Imaging System

InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has received 510(k) clearance from the United States Food and Drug Administration to market the LipiScan IVUS Coronary Imaging System. LipiScan IVUS is the first cardiac catheter to combine intravascular ultrasound and near-infrared spectroscopy to help cardiologists identify and characterize the plaques that complicate stenting and are associated with acute coronary events.

2 Sep 2010

CORDIS reports positive results from 10-year follow-up of CYPHER Sirolimus-eluting coronary stent study

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER(R) Sirolimus-eluting coronary stent have proven outstanding long-term efficacy and safety and were published earlier this year in "JACC: Cardiovascular Interventions".

31 Aug 2010

Drug-eluting stents improve long-term clinical outcome for patients undergoing angioplasty

Researchers at the Rabin Medical Center in Israel have determined that the use of drug-eluting stents (DES) improves the long-term clinical outcome for patients undergoing percutaneous coronary intervention (PCI), commonly known as angioplasty. Results of this study appear in the September issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.

19 Aug 2010

CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

The Cardiovascular Research Foundation has announced that in addition to the previously announced late breaking clinical trials and first reports, a series of additional featured trials will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. These trials will focus on a wide range of significant topics in interventional cardiovascular medicine. TCT 2010 will take place September 21 - 25 in Washington, DC.

13 Aug 2010

Restenosis News and Research

Further Reading

Novel drug-coated balloon technology adopted in niche applications across Europe: MRG

Atrium completes enrollment in iCAST Atrium Registry Ultrasound Study

Spectranetics 2010 third quarter revenue increases 3% to $29.6 million

EES implantation reduces restenosis, repeat revascularization in patients with calcified culprit lesions

Carotid artery stenting increases risk of death, stroke

OrbusNeich completes enrollment in randomized clinical study of Genous Bio-engineered R stent in China

IN.PACT drug-eluting balloons show promising results for superficial femoral artery disease treatment

Clinical trial results of Genous Bio-engineered R stent, EPC capture technology presented at TCT 2010

Boston releases HORIZONS-AMI trial data

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

Lutonix presents data on Moxy Drug Coated Balloon Catheter at TCT meeting

InspireMD to launch MGuard Prime MicroNet stent system at TCT Conference

TAXUS Element Stent has comparable levels of TLR and late loss in diabetic and non-diabetic patients

Boston announces TAXUS ATLAS clinical trial data for complex lesions

ESC recommends InspireMD MGuard mesh technology for thrombotic lesions

Late breaking clinical trials in interventional cardiovascular medicine to be presented at TCT 2010

InfraReDx receives 510(k) clearance to market LipiScan IVUS Coronary Imaging System

CORDIS reports positive results from 10-year follow-up of CYPHER Sirolimus-eluting coronary stent study

Drug-eluting stents improve long-term clinical outcome for patients undergoing angioplasty

CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News